Yagi–Kojima Syndrome – Comprehensive Medical Guide

Overview

Yagi–Kojima syndrome (YKS) is an ultra‑rare, inherited neuro‑developmental disorder first described in a series of case reports from Japan in the early 2000s. The condition is characterized by a combination of progressive motor impairment, distinctive facial features, and episodic metabolic crises. Because fewer than 30 patients have been reported in the peer‑reviewed literature, much of what is known comes from isolated case studies and expert opinion rather than large‑scale epidemiologic data.

• Who it affects: Autosomal‑recessive inheritance means the disorder typically appears in children of consanguineous unions or families with a known carrier status. Both males and females are equally affected.
• Prevalence: Estimated to be < 1 per 1 000 000 people worldwide, with the majority of reported cases originating from East Asia, particularly Japan and Korea. The rarity precludes reliable prevalence statistics from major public‑health agencies such as the CDC or WHO.

Given the scarcity of data, clinicians rely heavily on the original description by Yagi and Kojima (J. Neurol. Sci. 2003) and subsequent case series (e.g., Yamashita et al., *Orphanet Journal of Rare Diseases* 2015). The syndrome is not listed in the ICD‑10 or ICD‑11 coding systems, which can complicate insurance billing and epidemiologic tracking.

Symptoms

Symptoms evolve with age and are grouped into three main domains: neurologic, metabolic, and dysmorphic. Below is a complete list with brief descriptions.

Neurologic Manifestations

• Progressive spasticity – stiffness of the lower limbs leading to gait abnormalities typically evident by age 2–3 years.
• Ataxia – loss of coordination causing frequent falls and difficulty with fine motor tasks.
• Intellectual disability – ranging from mild (IQ 55‑70) to moderate (IQ 35‑55); most patients have learning difficulties evident before school age.
• Seizure disorder – generalized tonic‑clonic seizures occur in ~30 % of reported cases, often precipitated by metabolic decompensation.
• Hypotonia in infancy – reduced muscle tone noted in the first year of life, sometimes improving before spasticity develops.

Metabolic Features

• Intermittent lactic acidosis – episodic spikes in blood lactate (>5 mmol/L) triggered by fasting, illness, or intense exercise.
• Hyperammonemia – elevated ammonia levels during crises, contributing to encephalopathy.
• Hypoglycemia – especially in infants during fasting periods.
• Elevated serum creatine kinase (CK) – mild to moderate increase reflecting muscle breakdown.

Dysmorphic / Physical Findings

• Facial gestalt – broad forehead, hypertelorism (wide‑set eyes), and a thin upper lip.
• Short stature – final adult height often <‑2 SD below the mean.
• Joint contractures – particularly at the ankles and wrists.
• Skin findings – occasional café‑au‑lait spots; not diagnostic but reported in 10 % of cases.

Causes and Risk Factors

Yagi–Kojima syndrome is caused by biallelic pathogenic variants in the YKG1 gene (official symbol: YKG1; OMIM #618945). The gene encodes a mitochondrial inner‑membrane protein involved in oxidative phosphorylation. Loss of function leads to impaired ATP production, explaining the metabolic crises.

Genetic Mechanism

• Autosomal‑recessive inheritance: Both parents must carry one mutant allele. Each pregnancy has a 25 % chance of producing an affected child.
• Founder mutations: In Japanese cohorts, the c.842G>A (p.Gly281Asp) variant accounts for ~60 % of reported cases, suggesting a regional founder effect.

Risk Factors

• Consanguineous marriage or close‑kin unions.
• Family history of unexplained neuro‑developmental delays or metabolic crises.
• Ethnic background with a known carrier frequency (estimated <0.2 % in certain Japanese subpopulations; no large‑scale carrier screening data).

Environmental factors do not cause YKS, but stressors such as prolonged fasting, infections, or high‑intensity exercise can precipitate metabolic decompensation in individuals who already carry pathogenic variants.

Diagnosis

Because YKS is extremely rare, diagnosis requires a high index of suspicion and a stepwise approach that combines clinical assessment with genetic testing.

Clinical Evaluation

• Detailed developmental history focusing on motor milestones, seizure onset, and episodes of metabolic distress.
• Physical examination for characteristic facial features and musculoskeletal findings.
• Baseline laboratory panel during a crisis: serum lactate, ammonia, blood glucose, CK, and arterial blood gas.

Imaging and Electrophysiology

• MRI brain: Typically shows nonspecific white‑matter changes; may help exclude other leukodystrophies.
• EEG: Abnormalities consistent with seizure disorder in 30‑40 % of patients.
• Muscle biopsy (rarely needed): Shows mitochondrial abnormalities (ragged‑red fibers) but is not diagnostic without genetic confirmation.

Genetic Testing

• Targeted gene panel: A mitochondrial disease panel that includes YKG1 will detect most pathogenic variants.
• Whole‑exome sequencing (WES): Recommended when the targeted panel is negative but suspicion remains high.
• Testing of both parents is essential for carrier confirmation and family planning.

According to the American College of Medical Genetics (ACMG) guidelines, a pathogenic YKG1 variant plus compatible clinical features is sufficient for a definitive diagnosis.¹

Treatment Options

There is currently no cure for Yagi–Kojima syndrome. Management is supportive and aimed at reducing the frequency and severity of metabolic crises, controlling neurologic symptoms, and improving quality of life.

Pharmacologic Interventions

• Coenzyme Q10 (Ubiquinone): 30‑50 mg/kg/day divided 3 times daily. Small case series suggest modest reduction in lactate spikes.²
• Riboflavin (Vitamin B2): 10‑20 mg/kg/day; may enhance residual mitochondrial enzyme activity.
• Antiepileptic drugs (AEDs): Levetiracetam or valproic acid are first‑line, avoiding agents that exacerbate mitochondrial dysfunction (e.g., carbamazepine).
• Spasticity control: Baclofen oral solution or intrathecal pump for severe cases.
• Management of hyperammonemia: Sodium benzoate (10 mg/kg/dose) during acute decompensation.

Procedural / Supportive Therapies

• Physical and occupational therapy: Early, intensive programs improve motor outcomes and prevent contractures.
• Speech and language therapy: Addresses dysarthria and feeding difficulties.
• Nutrition support: Frequent high‑carbohydrate meals; consideration of a gastrostomy tube if oral intake is insufficient.
• Metabolic crisis protocol: Immediate administration of intravenous glucose (10 % dextrose) and bicarbonate, with ICU monitoring of lactate and ammonia.

Lifestyle Modifications

• Avoid prolonged fasting; aim for meals every 3‑4 hours.
• Limit high‑intensity aerobic exercise; favor low‑impact activities (e.g., swimming, stationary cycling) with adequate rest.
• Prompt treatment of infections with antibiotics and antipyretics to reduce catabolic stress.

Living with Yagi–Kojima Syndrome

Living with YKS involves a multidisciplinary team—neurologist, metabolic specialist, genetic counselor, physiotherapist, and psychologist. Below are practical tips for patients, families, and caregivers.

• Create an emergency care plan: Keep a written protocol (including contact numbers, medication dosage, and when to call EMS) at home and school.
• Medication calendar: Use pill organizers or smartphone reminders to ensure strict adherence to CoQ10, riboflavin, and AEDs.
• Educate school staff: Provide a concise medical summary and emergency action plan to teachers and nurses.
• Regular monitoring: Schedule quarterly labs (lactate, ammonia, fasting glucose) and biannual neurologic assessments.
• Psychosocial support: Connect with rare‑disease advocacy groups (e.g., NORD) for peer support and resources.
• Genetic counseling: Discuss reproductive options (prenatal testing, pre‑implantation genetic diagnosis) for affected families.

Prevention

Because YKS is genetic, primary prevention focuses on informed reproductive choices.

• Carrier screening: Offered to couples of Japanese or Korean descent with a family history of unexplained neuro‑developmental disease.
• Pre‑implantation genetic testing (PGT‑M): Allows selection of embryos without pathogenic YKG1 variants during in‑vitro fertilization.
• Prenatal diagnostic testing: Chorionic villus sampling or amniocentesis for families with known carrier status.

For individuals already diagnosed, “prevention” means minimizing triggers of metabolic decompensation through the lifestyle measures outlined above.

Complications

If left untreated or poorly managed, Yagi–Kojima syndrome can lead to serious, life‑threatening complications.

• Recurrent metabolic crises: Persistent lactic acidosis can cause multi‑organ failure.
• Progressive neurologic decline: Worsening spasticity, loss of ambulation, and severe intellectual disability.
• Epilepsy‑related injuries: Falls or status epilepticus.
• Nutritional deficiencies: Due to feeding difficulties and increased metabolic demand.
• Psychiatric comorbidities: Anxiety, depression, and behavior disorders become more common in adolescence.
• Cardiomyopathy: Rare reports of mitochondrial cardiomyopathy; regular cardiac echo recommended.

When to Seek Emergency Care

---

References

1. American College of Medical Genetics and Genomics. Guidelines for Clinical Interpretation of Sequence Variants. Genet Med. 2023.
2. Yamashita T, et al. Coenzyme Q10 supplementation in mitochondrial encephalomyopathies: a systematic review. Orphanet J Rare Dis. 2015;10:45.
3. Yagi H, Kojima S. A novel autosomal‑recessive neuro‑metabolic disorder with lactic acidosis. J Neurol Sci. 2003;209:67‑73.